{
    "clinical_study": {
        "@rank": "127623", 
        "acronym": "Ifabond", 
        "arm_group": [
            {
                "arm_group_label": "Arm A: Applying Ifabond", 
                "arm_group_type": "Experimental", 
                "description": "The synthetic adhesive solution Ifabond, will be applied at the end of conventional breast cancer surgery for arm A patients."
            }, 
            {
                "arm_group_label": "Arm B: without Ifabond", 
                "arm_group_type": "No Intervention", 
                "description": "The synthetic adhesive solution Ifabond, will not be applied at the end of conventional breast cancer surgery in arm B patients."
            }
        ], 
        "brief_summary": {
            "textblock": "A randomized prospective simple-blind interventional study evaluating the efficacy of the\n      synthetic adhesive solution \"Ifabond\", in patients undergoing breast cancer surgery. The\n      main objective of this study is to determine if the application of Ifabond, in addition to\n      the conventional method of breast surgery, reduces the postoperative seroma formation. The\n      secondary objective is to assess quality of life immediately after surgery, and the need for\n      needle aspiration of the axilla, when using Ifabond."
        }, 
        "brief_title": "Efficacy Study of Ifabond in Breast Cancer Surgery", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Cancer", 
            "Lymphocele"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Lymphocele"
            ]
        }, 
        "detailed_description": {
            "textblock": "Breast cancer patients will be selected at their preoperative visit with the surgeon, who\n      will inform them about the study and answer their questions.\n\n      Patients who consent to participate will be randomized to one of two arms:\n\n        1. Arm A: Applying Ifabond\n\n        2. Arm B: Without Ifabond\n\n      Patients will be stratified according to these two criteria:\n\n        1. Axillary Lymph Node Dissection planned (ALND)\n\n        2. Body Mass Index (BMI)\n\n      The following parameters will be measured:\n\n        -  ECOG status and Blood Pressure at day 3(day 7 in case of ALND), day 15 and day 30 post\n           surgery\n\n        -  Volume of drainage at day 3 and at (day 7 in case of ALND)post surgery\n\n        -  Discomfort alleged by the patient at day 3(day 7 in case of ALND), day 15 and day 30\n           post surgery\n\n        -  Lymphocele volume measured by ultrasound at day 15 and day 30 post surgery\n\n        -  If the volume is \u2265 100cc, a needle aspiration will be performed, and the volume of\n           aspirate will be documented.\n\n        -  Adverse events and concomitant medications will be collected throughout the study until\n           30 days after the last ultrasound."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \"Eastern Cooperative Oncology Group\" ECOG status \u2264 2\n\n          -  Diagnosis of invasive or In situ breast cancer\n\n          -  Patient undergoing partial mastectomy with or without axillary lymph node\n             dissection,(without communication between the two surgical loges)\n\n        Exclusion Criteria:\n\n          -  Pregnant or breast-feeding patient\n\n          -  Participation at another protocol with an Investigational drug (within the last 4\n             weeks before enrollment)\n\n          -  Known hypersensitivity to Cyanoacrylate\n\n          -  Known hypersensitivity to formaldehyde\n\n          -  Patient who experience systemic infections preoperatively, or have conditions that\n             are known to interfere with the healing process\n\n          -  Patient with uncontrolled diabetes"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "102", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01742975", 
            "org_study_id": "RCB ID: 2011-A01014-37"
        }, 
        "intervention": {
            "arm_group_label": "Arm A: Applying Ifabond", 
            "description": "The synthetic adhesive solution Ifabond, will be applied at the end of conventional breast cancer surgery for arm A patients", 
            "intervention_name": "IFABOND (TM)", 
            "intervention_type": "Device", 
            "other_name": "An authorized device with CE labeling."
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 5, 2012", 
        "location": [
            {
                "contact": {
                    "email": "w_bidaut@ch-ambroisepare.fr", 
                    "last_name": "Wahiba BIDAUT, senior CRA", 
                    "phone": "(33)4-91-83-38-38", 
                    "phone_ext": "3155"
                }, 
                "contact_backup": {
                    "email": "mp_sow@ch-ambroisepare.fr", 
                    "last_name": "Penda SOW, CRA", 
                    "phone": "(33)4-91-83-38-38", 
                    "phone_ext": "3105"
                }, 
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "state": "Paca", 
                        "zip": "13006"
                    }, 
                    "name": "H\u00f4pital Ambroise Par\u00e9"
                }, 
                "investigator": [
                    {
                        "last_name": "Michel CONTE, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Bernard BLANC, MD/prof", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Didier MATHIEU, MD/prof", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Jean QUILICHINI, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "raoul.payan@hotmail.fr", 
                    "last_name": "Raoul PAYAN, MD", 
                    "phone": "04-76-42-98-01"
                }, 
                "facility": {
                    "address": {
                        "city": "Grenoble", 
                        "country": "France", 
                        "state": "Rh\u00f4ne-Alpes", 
                        "zip": "38000"
                    }, 
                    "name": "Centre de Chirurgie Gynecologique Et Des Maladies Du Sein"
                }, 
                "investigator": {
                    "last_name": "Raoul PAYAN, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Study Evaluating the Efficacy of the Synthetic Adhesive Solution Ifabond, in Reducing Seroma Formation Post Surgery in Breast Cancer Patients, When Used in Partial Mastectomy With or Without Axillary Lymph Node Dissection", 
        "other_outcome": {
            "description": "The number of needle aspiration required at day 15 and day30 (-or- 2 days)  post surgery will be documented.", 
            "measure": "Change in the number of needle aspiration required", 
            "safety_issue": "No", 
            "time_frame": "day 15 and day 30"
        }, 
        "overall_contact": {
            "email": "w_bidaut@ch-ambroisepare.fr", 
            "last_name": "Wahiba BIDAUT, senior CRA", 
            "phone": "(33)4-91-83-38-38", 
            "phone_ext": "3155"
        }, 
        "overall_contact_backup": {
            "email": "mp_sow@ch-ambroisepare.fr", 
            "last_name": "Penda SOW, CRA", 
            "phone": "(33)4-91-83-38-38", 
            "phone_ext": "3105"
        }, 
        "overall_official": {
            "affiliation": "H\u00f4pital Ambroise Par\u00e9, Marseille", 
            "last_name": "Michel CONTE, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: ANSM (Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9)", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The volume of drain at Day 3 (or 7 in case of axillary lymph node dissection) post surgery will be documented, then patients will have an ultrasound exam at day 15 and day 30 (+or- 2 days) to measure seroma.", 
            "measure": "Change in seroma formation", 
            "safety_issue": "No", 
            "time_frame": "Day 3 (or 7 in case of axillary lymph node dissection), day15 and day 30 post surgery"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01742975"
        }, 
        "responsible_party": {
            "investigator_affiliation": "H\u00f4pital Ambroise Par\u00e9", 
            "investigator_full_name": "Michel Conte, M.D.", 
            "investigator_title": "Michel CONTE, obstetrician gynecologist surgeon", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Patients will be asked if they feel any discomfort in relation to seroma formation at Day 3 (or 7 in case of axillary lymph node dissection),day15 and day 30 (-or- 2 days) post surgery.", 
            "measure": "Change in discomfort alleged by the patient", 
            "safety_issue": "No", 
            "time_frame": "day 3 (or 7), day 15 and day 30"
        }, 
        "source": "H\u00f4pital Europ\u00e9en Marseille", 
        "sponsors": {
            "collaborator": {
                "agency": "IfaMEDICAL", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "H\u00f4pital Europ\u00e9en Marseille", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}